Celgene Sues Hikma To Block Revlimid Generic

Law360 (April 29, 2021, 5:02 PM EDT) -- Celgene has hit Hikma Pharmaceuticals USA Inc. with a lawsuit in New Jersey federal court seeking to block Hikma from marketing generic versions of the Bristol-Myers Squibb unit's cancer drug Revlimid.

In a patent infringement complaint Wednesday, Celgene Corp. challenged an abbreviated new drug application, or ANDA, that Hikma Pharmaceuticals USA Inc. submitted to the U.S. Food and Drug Administration.

The ANDA is asking the government to allow Hikma to "to manufacture, use, import, distribute, offer to sell and/or sell generic versions of Celgene's Revlimid drug products" before various patents covering the brand-name product have expired, the suit said.

"Unless enjoined...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!